Literature DB >> 21593124

Risk assessment of moderate to severe alcohol withdrawal--predictors for seizures and delirium tremens in the course of withdrawal.

Florian Eyer1, Tibor Schuster, Norbert Felgenhauer, Rudi Pfab, Tim Strubel, Bernd Saugel, Thomas Zilker.   

Abstract

AIMS: To develop a prediction model for withdrawal seizures (WS) and delirium tremens (DT) during moderate to severe alcohol withdrawal syndrome (AWS) in a large cohort of inpatients treated for AWS (n = 827).
METHODS: Re-analysis of a cohort study population treated between 2000 and 2009. All patients received a score-guided and symptom-triggered therapy for AWS. Multivariable binary logistic regression models with stepwise variable selection procedures were conducted providing odds ratio (OR) estimates.
RESULTS: In the multivariable regression, significant predictors of WS during AWS therapy were a delayed climax of withdrawal severity since admission [OR/10 h: 1.23; 95% confidence interval (CI): 1.1-1.4; P < 0.001)], prevalence of structural brain lesions in the patient's history (OR 6.5; 95% CI: 3.0-14.1; P < 0.001) and WS as the cause of admittance (OR 2.6; 95% CI: 1.4-4.8; P = 0.002). Significant predictors at admission for the occurrence of DT were lower serum potassium (OR/1 mmol/l 0.33; 95% CI: 0.17-0.65; P = 0.001), a lower platelet count (OR/100.000 0.42; 95% CI: 0.26-0.69; P = 0.001) and prevalence of structural brain lesions (OR 5.8; 95% CI: 2.6-12.9; P < 0.001).
CONCLUSION: In this large retrospective cohort, some easily determinable parameters at admission may be useful to predict a complicated course of alcohol withdrawal regarding the occurrence of WS or DT. Using the provided nomograms, clinicians can estimate the percentage likelihood of patients to develop either WS or DT during their course of withdrawal. Prevalence of structural brain lesions in the patient's history does strongly warrant a careful observation of patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593124     DOI: 10.1093/alcalc/agr053

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  27 in total

1.  The role of a medical toxicologist for assistance in the treatment of alcohol withdrawal syndrome.

Authors: 
Journal:  J Med Toxicol       Date:  2012-06

2.  The management of alcohol use disorders: the impact of pharmacologic, affective, behavioral, and cognitive approaches.

Authors:  Jocelyn Carter; Estee Sharon; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2014-08-21

3.  DNA damage and oxidative stress induced by seizures are decreased by anticonvulsant and neuroprotective effects of lobeline, a candidate to treat alcoholism.

Authors:  Liana Dantas da Costa E Silva; Patrícia Pereira; Gabriela Gregory Regner; Fernanda Brião Menezes Boaretto; Cleonice Hoffmann; Pricila Pflüger; Lucas Lima da Silva; Luiza Reinhardt Steffens; Ana Moira Morás; Dinara Jaqueline Moura; Jaqueline Nascimento Picada
Journal:  Metab Brain Dis       Date:  2017-10-14       Impact factor: 3.584

4.  Rapid temporal changes in the expression of a set of neuromodulatory genes during alcohol withdrawal in the dorsal vagal complex: molecular evidence of homeostatic disturbance.

Authors:  Kate Freeman; Mary M Staehle; Zeynep H Gümüş; Rajanikanth Vadigepalli; Gregory E Gonye; Carmen N Nichols; Babatunde A Ogunnaike; Jan B Hoek; James S Schwaber
Journal:  Alcohol Clin Exp Res       Date:  2012-04-06       Impact factor: 3.455

Review 5.  Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond.

Authors:  Ankur Sachdeva; Mona Choudhary; Mina Chandra
Journal:  J Clin Diagn Res       Date:  2015-09-01

Review 6.  Molecular and neurologic responses to chronic alcohol use.

Authors:  B N Costin; M F Miles
Journal:  Handb Clin Neurol       Date:  2014

Review 7.  Structural and microstructral imaging of the brain in alcohol use disorders.

Authors:  Natalie M Zahr
Journal:  Handb Clin Neurol       Date:  2014

Review 8.  Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary.

Authors:  Don-Kelena Awissi; Genevieve Lebrun; Douglas B Coursin; Richard R Riker; Yoanna Skrobik
Journal:  Intensive Care Med       Date:  2012-11-27       Impact factor: 17.440

Review 9.  Neuroimaging in alcohol use disorder: From mouse to man.

Authors:  Michael Fritz; Anna M Klawonn; Natalie M Zahr
Journal:  J Neurosci Res       Date:  2019-04-22       Impact factor: 4.164

10.  Quantifying the clinical significance of cannabis withdrawal.

Authors:  David J Allsop; Jan Copeland; Melissa M Norberg; Shanlin Fu; Anna Molnar; John Lewis; Alan J Budney
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.